Turing boss Martin Shkreli says Daraprim price drop 'might curtail research for lethal diseases'

Boss of controversial pharmaceutical company that increased price of life-saving drug overnight claims being forced to slash price again may force him to cut research and fire staff

Martin Shkreli, boss of the controversial pharmaceutical company that increased the price of its life-saving drug 50-fold overnight, has claimed slashing the price of the drug may lead him to cut research for "lethal diseases" and force him to fire staff.

After intense pressure, including criticism from presidential hopeful Hillary Clinton, Shkreli confirmed this week he will slash the price of Daraprim, a drug his company, Turing Pharmaceuticals, bought in August and then hiked from $13.50 to $750 a pill.